Johnson & Johnson (JNJ)

Trump to highlight investments from top companies, including Nvidia, J&J, and Toyota, in 'Investing in America' event to mark first 100 days in office.

A lawsuit claims Eli Lilly, Johnson & Johnson, and Kaiser Permanente failed to warn consumers about breast cancer risks linked to their antipsychotic drugs Risperdal and Zyprexa.

Analysts raise AbbVie price targets after strong Q1 results, driven by Skyrizi, Rinvoq growth and strategic moves in Parkinson's disease treatments.

See these three stocks that are among the most important in their industries, which have announced sizable increases in their dividends.

The companies are working on treatments for a form of bladder cancer.

See these three top-10 stocks in the pharmaceutical industry that are pledging investment in the United States totalling over $100 billion.

Short-term tariff uncertainty marks the perfect opportunity for long-term investors to snag some amazing deals.

Global pharmaceutical company Merck (NYSE:MRK) will be reporting results tomorrow before market hours. Here’s what to expect.

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be announcing earnings results tomorrow morning. Here’s what investors should know.

The Trump Administration is reportedly mulling over a policy to match U.S. drug prices with those in other developed nations.

Multinational healthcare company Johnson & Johnson (NYSE:JNJ) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 2.4% year on year to $21.89 billion. The company’s full-year revenue guidance of $92 billion at the midpoint came in 1.8% above analysts’ estimates. Its non-GAAP profit of $2.77 per share was 7.3% above analysts’ consensus estimates.

Roche to invest $50 billion in U.S. over five years, adding 12,000+ jobs and expanding manufacturing, R&D, and export capacity across eight states.

Johnson & Johnson has been treading water for the past six months, recording a small loss of 3.8% while holding steady at $157.30. However, the stock is beating the S&P 500’s 11% decline during that period.

Stock market expert Jon Erlichman recently shared a review of stock returns during the last six U.S. recessions, highlighting those that have performed well in difficult times.

I’ve adopted “SWAN,” which stands for

Healthcare sector sees volatility due to UnitedHealth's earnings disappointment, but ETFs like XLV, IHE, and XPH still show resilience and pockets of strength.